o	Poster session on lead program abi-suva at AACR and scientific presentations
on the individualized cancer vaccine (VB10.NEO) and the tolerance program at
NextGen Biomed 


Oslo, Norway, March 18, 2026 - Nykode Therapeutics ASA (OSE: NYKD), a
clinical-stage biopharmaceutical company dedicated to the discovery and
development of novel immunotherapies, today announced upcoming presentations at
the 2026 American Association for Cancer Research (AACR) Annual Meeting and
NextGen Biomed 2026.

The AACR Annual Meeting will take place April 17-22, 2026 in San Diego,
California, and NextGen Biomed 2026 will be held March 24-26, 2026 in London,
United Kingdom.

Presentation Details: 

AACR Poster Session (abi-suva) 
Session title: Phase I Clinical Trials
Title: Immunogenicity of the therapeutic HPV16-specific cancer vaccine
abipapogene suvaplasmid (VB10.16) in combination with pembrolizumab given as 1L
treatment for HPV16+ PD-L1+ r/m oropharyngeal cancer: preliminary results from
phase 1 of the VB-C-03 trial

Location: Poster Section 50
Poster Board Number: 9
Date: April 21, 2026
Time: 09:00 AM - 12:00 PM PDT

NextGen Biomed Presentation (VB10.NEO)
Title: VB10.NEO: The Journey of a Clinically Validated Individualized Cancer
Therapy from Tumour Biopsy to Vaccine Administration

Date: March 24, 2026
Time: 11:40-12:00 GMT

NextGen Biomed Presentation (Tolerance):
Title: Development Of APC-Targeted Antigen-Specific Immune Tolerance Therapies
For Autoimmune Diseases

Date: March 25, 2026
Time: 12:00-12:25 GMT

The presentation slides will be available after the presentations at the
Company's webpage:
https://nykode.com/research-and-development/scientific-papers-and-presentations/


About Nykode Therapeutics
Nykode Therapeutics is a clinical-stage biopharmaceutical company dedicated to
the discovery and development of novel immunotherapies with a focus on the
treatment of cancer and autoimmune diseases. Nykode's modular immunotherapy
technology specifically targets antigens to antigen presenting cells (APC),
which have been shown to induce a broad, strong and long-lasting antigen
specific immune response in cancer, which correlates with clinical responses.

Nykode's lead product candidates are abi-suva, a therapeutic immunotherapy for
the treatment of HPV16 induced malignancies which demonstrated favorable safety
and efficacy results from its Phase 2 trial for the treatment of late-line r/m
cervical cancer. Abi-suva is currently being further developed in first line
head and neck cancer with the randomized Abili-T trial with interim results
within 2027. VB10.NEO, an individualized cancer neoantigen immunotherapy, has
been investigated in two trials with more than 10 different indications. 

Nykode is also utilizing its APC-targeted technology to create an immune
tolerance platform for the potential use in autoimmune disorders, organ
transplant rejections, anti-drug antibody reactions and allergy.

Nykode Therapeutics' shares are traded on the Oslo Stock Exchange (OSE: NYKD).
Further information about Nykode Therapeutics can be found at
http://www.nykode.com.

Forward-looking statements for Nykode Therapeutics
This announcement and any materials distributed in connection with this
announcement may contain certain forward-looking statements. By their nature,
forward-looking statements involve risk and uncertainty because they reflect the
company's current expectations and assumptions as to future events and
circumstances that may not prove accurate. A number of material factors could
cause actual results and developments to differ materially from those expressed
or implied by these forward-looking statements.

Contact for Nykode Therapeutics ASA:
IR@nykode.com
Nykode Therapeutics ASA

Oslo Science Park
Gaustadalléen 21
N-0349 Oslo, Norway